Key result
In Japanese patients with nonvalvular atrial fibrillation, warfarin treatment reduced the annual incidence of thromboembolic events compared to no warfarin (OR 0.49), and the mCHA2DS2-VASc score successfully identified patients at truly low risk.
Why the study?
Are the modified CHA2DS2-VASc and HAS-BLED scores valid for stratifying thromboembolic and major bleeding risks in Japanese patients with nonvalvular atrial fibrillation?
Observational (n=7,384)
Yes
Are the modified CHA2DS2-VASc and HAS-BLED scores valid for stratifying thromboembolic and major bleeding risks in Japanese patients with nonvalvular atrial fibrillation?
Odds Ratio: 0.49 (95% CI 0.33–0.74)
Absolute Event Rate: 0.8% vs 1.5%
p-value: p=0.0007
The modified CHA2DS2-VASc and HAS-BLED scores are useful for identifying Japanese NVAF patients at truly low risk of thromboembolism and high risk of major bleeding, respectively, and female sex may be excluded as a risk factor.
No takes yet. Share an insight, caveat, or question.
Supports CHA2DS2-VASc/HAS-BLED risk stratification in Japanese NVAF; extends Caucasian data but leaves prospective outcome trials open.
Okumura et al. (2014) conducted an observational in Nonvalvular Atrial Fibrillation (n=7,384). Warfarin vs. Non-warfarin was evaluated on Thromboembolism (OR 0.49, 95% CI 0.33-0.74, p=0.0007). In Japanese patients with nonvalvular atrial fibrillation, warfarin treatment reduced the annual incidence of thromboembolic events compared to no warfarin (OR 0.49), and the mCHA2DS2-VASc score successfully identified patients at truly low risk.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: